AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus

A patient suffering from a life-threatening staphylococcal endocarditis received AB-SA01 under expanded access regulatory guidelines CATEGORY: Featured Monday, September 11, 2017 6:50 am EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “We continue implementation of our strategy to work with leading infectious disease physicians in the United States and Australia and […]

AmpliPhi Biosciences Announces Receipt of $2.0 Million R&D Tax Incentive

Wednesday, September 6, 2017 6:50 am EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “The R&D tax rebate is an important source of non-dilutive capital and we appreciate the Australian government’s support as we develop our novel bacteriophage therapies aimed at combatting the growing global threat of antibiotic resistance” SAN DIEGO–(BUSINESS […]

AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer

CATEGORY: Featured Wednesday, May 31, 2017 4:05 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces the appointment of Paul C. Grint, M.D. as Chief Executive Officer, […]

AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights

Monday, May 15, 2017 4:01 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “In parallel, we are seeking opportunities to advance our chronic rhinosinusitis (CRS) and preclinical cystic fibrosis (CF) programs, potentially through partnerships and/or non-dilutive funding.” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development […]

AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalized Therapies for Serious or Life-Threatening Antibiotic-Resistant Infections

Monday, May 1, 2017 6:50 am EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “stated that the clinical safety and effectiveness data collected during development, including from emergency case studies, could inform future discussions for clinical development and, ultimately, the regulatory pathway to approval.” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: […]

AmpliPhi Biosciences Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Thursday, November 10, 2016 5:27 pm EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB US03211P1030 “AmpliPhi has made tremendous progress this quarter, demonstrated by the announcement of topline data from clinical trials of both of our lead development programs, including the first U.S.-based trial of AB-SA01” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation […]

AmpliPhi Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

CATEGORY: Featured Thursday, November 17, 2016 8:45 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB US03211P1030 SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced the pricing of an underwritten public offering of 5,335,000 shares of its […]

AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients

AB-SA01 meets primary endpoints of safety and tolerability and reduces S. aureus bacterial load in all patients Business update call scheduled for January 4, 2017 at 4:30 p.m. Eastern CATEGORY: Featured Monday, December 19, 2016 8:45 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB US03211P1030 “We are delighted with the […]

Renowned Sinus Surgeon Dr. Peter-John Wormald Comments on AmpliPhi Biosciences’ Favorable Phase 1 Results of AB-SA01 in Chronic Rhinosinusitis Patients

Business update call scheduled for today at 4:30 p.m. Eastern CATEGORY: Featured Wednesday, January 4, 2017 8:45 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “We saw decreases in S. aureus bacterial load in all patients treated with AB-SA01 in our Phase 1 trial, which is particularly encouraging since most […]

AmpliPhi Biosciences Terminates Collaboration Agreement with Intrexon

SAN DIEGO, April 14, 2016 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has provided written notice to Intrexon to cancel the Exclusive Channel Collaboration (ECC) with Intrexon. Under the terms of the agreement, AmpliPhi has the […]